Beitnes Jan Otto, Lunde Ketil, Brinchmann Jan E, Aakhus Svend
Department of Cardiology, Oslo University Hospital, Rikshospitalet, Nydalen, Oslo, Norway.
Expert Rev Cardiovasc Ther. 2011 Aug;9(8):1015-25. doi: 10.1586/erc.11.108.
Despite recent advances in medical therapy, reperfusion strategies, implantable cardioverter-defibrillators and cardiac assist devices, ischemic heart disease is a frequent cause of morbidity and mortality worldwide. Cell therapy has been introduced as a new treatment modality to regenerate lost cardiomyocytes. At present, several cell types seem to improve left ventricular function in animal models as well as in humans, but evidence for true generation of new myocardium is confined to the experimental models. In the clinical perspective, myocardial regeneration has been replaced by myocardial repair, as other mechanisms seem to be involved. Clinical studies on adult stem cells suggest, at best, moderate beneficial effects on surrogate end points, but some applications may qualify for evaluation in larger trials. Complete regeneration of the myocardium by cell therapy after a large myocardial infarction is still visionary, but pluripotent stem cells and tissue engineering are important tools to solve the puzzle.
尽管在药物治疗、再灌注策略、植入式心脏复律除颤器及心脏辅助装置方面取得了最新进展,但缺血性心脏病仍是全球发病率和死亡率的常见原因。细胞治疗作为一种新的治疗方式被引入,用于再生丢失的心肌细胞。目前,几种细胞类型似乎在动物模型以及人类中都能改善左心室功能,但真正产生新心肌的证据仅限于实验模型。从临床角度来看,心肌再生已被心肌修复所取代,因为似乎涉及其他机制。关于成体干细胞的临床研究充其量表明对替代终点有适度的有益影响,但一些应用可能有资格在更大规模的试验中进行评估。心肌梗死面积较大后通过细胞治疗实现心肌完全再生仍是一种设想,但多能干细胞和组织工程是解决这一难题的重要工具。